Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population

References

• Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011;52(Suppl2):3-9
   Web of Science ®Google Scholar
• Dravet C. Dravet syndrome history. Dev Med Child Neurol 2011;53(Suppl2):1-6
   Web of Science ®Google Scholar
• Akiyama M, Kobayashi K, Yoshinaga H, et al. A long-term follow-up study of Dravet syndrome up to adulthood. Epilepsia 2010;51:1043-52
   PubMed Web of Science ®Google Scholar
• Chieffo D, Battaglia D, Lettori D, et al. Neuropsychological development in children with Dravet syndrome. Epilepsy Res 2011;95:86-93
   PubMed Web of Science ®Google Scholar
• Cooper MS, McIntosh A, Crompton DE, et al. Mortality in Dravet syndrome. Epilepsy Res 2016;128:43-7
   PubMed Web of Science ®Google Scholar
• Dhamija R, Erickson MK, St Louis EK, et al. Sleep abnormalities in children with Dravet syndrome. Pediatr Neurol 2014;50:474-8
   PubMed Web of Science ®Google Scholar
• Genton P, Velizarova R, Dravet C. Dravet syndrome: the long-term outcome. Epilepsia 2011;52(Suppl2):44-9
   Web of Science ®Google Scholar
• Ragona F, Granata T, Dalla Bernardina B, et al. Cognitive development in Dravet syndrome: a retrospective, multicenter study of 26 patients. Epilepsia 2011;52:386-92
   PubMed Web of Science ®Google Scholar
• Wolff M, Casse-Perrot C, Dravet C. Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings. Epilepsia 2006;47(Suppl2):45-8
   Web of Science ®Google Scholar
• Bayat A, Hjalgrim H, Moller RS. The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22,000: a population-based study from 2004 to 2009. Epilepsia 2015;56:e36-9
   PubMed Web of Science ®Google Scholar
• Brunklaus A, Ellis R, Reavey E, et al. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain 2012;135:2329-36
   PubMed Web of Science ®Google Scholar
• Wirrell EC. Treatment of Dravet syndrome. Can J Neurol Sci 2016;43(Suppl3):S13-S18
   Web of Science ®Google Scholar
• Munro JF, Seaton DA, Duncan LJ. Treatment of refractory obesity with fenfluramine. Br Med J 1966;2:624-5
   PubMed Web of Science ®Google Scholar
• Abenhaim L, Moride Y, Brenot F, et al. International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16
   PubMed Web of Science ®Google Scholar
• Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8
   PubMed Web of Science ®Google Scholar
• Onakpoya IJ, Heneghan CJ, Aronson JK. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. Crit Rev Toxicol 2016;46:477-89
   PubMed Web of Science ®Google Scholar
• Schoonjans A-S, Lagae L, Ceulemans B. Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Ther Adv Neurol Disord 2015;8:328-38
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 2012;53:1131-9
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Schoonjans A-S, Marchau F, et al. Five-year extended follow-up of 10 Dravet patients treated with fenfluramine. Epilepsia 2016;57:e129-e134
   PubMed Web of Science ®Google Scholar
• Schoonjans A-S, Paelinck B, Marchau F, et al. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome. Eur J Neurol 2017;24:309-14
   PubMed Web of Science ®Google Scholar
• Bowen R, Glicklich A, Khan M, et al. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061-6
   PubMedGoogle Scholar
• Douglas JG, Munro JF, Kitchin AH, et al. Pulmonary hypertension and fenfluramine. Br Med J (Clin Res Ed) 1981;283:881-3
   PubMed Web of Science ®Google Scholar
• McMurray J, Bloomfield P, Miller HC. Irreversible pulmonary hypertension after treatment with fenfluramine. Br Med J (Clin Res Ed) 1986;292:239-40
   PubMed Web of Science ®Google Scholar
• Rich S, Rubin L, Walker AM, et al. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000;117:870-4
   PubMed Web of Science ®Google Scholar
• Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008;31:343-8
   PubMed Web of Science ®Google Scholar
• Montani D, Seferian A, Savale L, et al. Drug-induced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev 2013;22:244-50
   PubMedGoogle Scholar
• Loke YK, Derry S, Pritchard-Copley A. Appetite suppressants and valvular heart disease - a systematic review. BMC Clin Pharmacol 2002;2:6
   PubMedGoogle Scholar
• Dahl CF, Allen MR, Urie PM, et al. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 2008;6:34
   PubMed Web of Science ®Google Scholar
• Sachdev M, Miller WC, Ryan T, et al. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 2002;144:1065-73
   PubMed Web of Science ®Google Scholar
• Hopkins PN, Polukoff GI. Risk of valvular heart disease associated with use of fenfluramine. BMC Cardiovasc Disord 2003;3:5
   PubMed Web of Science ®Google Scholar
• Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998;339:719-24
   PubMed Web of Science ®Google Scholar
• Li R, Serdula MK, Williamson DF, et al. Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy. Int J Obes Relat Metab Disord 1999;23:926-8
   PubMed Web of Science ®Google Scholar
• Droogmans S, Kerkhove D, Cosyns B, et al. Role of echocardiography in toxic heart valvulopathy. Eur J Echocardiogr 2009;10:467-76
   PubMed Web of Science ®Google Scholar
• Kimmel SE, Keane MG, Crary JL, et al. Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota. Am J Cardiol 1999;84:304-8
   PubMed Web of Science ®Google Scholar
• Schoonjans A-S, Marchau F, Paelinck B, et al. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: update of the prospective study. Presented at the 70th Annual Meeting of the American Epilepsy Society; December 2–6, 2016; Houston, TX
   Google Scholar
• Schoonjans A-S, Marchau F, Paelinck B, et al. Long-term efficacy and safety of low-dose fenfluramine treatment in Dravet syndrome: follow-up of the original patient cohort. Presented as part of Zogenix scientific exhibit. 70th Annual Meeting of the American Epilepsy Society; December 2–6, 2016; Houston, TX
   Google Scholar
• Boel M, Casaer P. Add-on therapy of fenfluramine in intractable self-induced epilepsy. Neuropediatrics 1996;27:171-3
   PubMed Web of Science ®Google Scholar
• Claes L, Del-Favero J, Ceulemans B, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001;68:1327-32
   PubMed Web of Science ®Google Scholar
• Yao W, Mu W, Zeifman A, et al. Fenfluramine-induced gene dysregulation in human pulmonary artery smooth muscle and endothelial cells. Pulm Circ 2011;1:405-18
   PubMedGoogle Scholar
• Fuller RW, Snoddy HD, Robertson DW. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol Biochem Behav 1988;30:715-21
   PubMed Web of Science ®Google Scholar
• Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-41
   PubMed Web of Science ®Google Scholar
• Connolly MB. Dravet syndrome: diagnosis and long-term course. Can J Neurol Sci 2016;43(Suppl3):S3-S8
   Web of Science ®Google Scholar
• Brunklaus A, Dorris L, Zuberi SM. Comorbidities and predictors of health-related quality of life in Dravet syndrome. Epilepsia 2011;52:1476-82
   PubMed Web of Science ®Google Scholar
• Burger AJ, Charlamb MJ, Singh S, et al. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs. Int J Cardiol 2001;79:159-65
   PubMed Web of Science ®Google Scholar
• Fisher EA, Ruden R. Pulmonary artery pressures and valvular lesions in patients taking diet suppressants. Cardiovasc Rev Rep 1998;19:13-16
   Google Scholar
• Kancherla MK, Salti HI, Mulderink TA, et al. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol 1999;84:1335-8
   PubMed Web of Science ®Google Scholar
• Lepor NE, Gross SB, Daley WL, et al. Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. Am J Cardiol 2000;86:107-10
   PubMed Web of Science ®Google Scholar
• Teramae CY, Connolly HM, Grogan M, et al. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc 2000;75:456-61
   PubMed Web of Science ®Google Scholar
• Wadden TA, Berkowitz RI, Silvestry F, et al. The fen-phen finale: a study of weight loss and valvular heart disease. Obes Res 1998;6:278-84
   PubMedGoogle Scholar
• Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283:1703-9
   PubMed Web of Science ®Google Scholar
• Hensrud DD, Connolly HM, Grogan M, et al. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc 1999;74:1191-7
   PubMed Web of Science ®Google Scholar
• Jollis JG, Landolfo CK, Kisslo J, et al. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000;101:2071-7
   PubMed Web of Science ®Google Scholar
• Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339:713-18
   PubMed Web of Science ®Google Scholar
• Shively BK, Roldan CA, Gill EA, et al. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999;100:2161-7
   PubMed Web of Science ®Google Scholar
• Wee CC, Phillips RS, Aurigemma G, et al. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med 1998;129:870-4
   PubMed Web of Science ®Google Scholar
• Weissman NJ, Tighe JF Jr, Gottdiener JS, et al. Sustained-Release Dexfenfluramine Study Group. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med 1998;339:725-32
   PubMed Web of Science ®Google Scholar
• Davidoff R, McTiernan A, Constantine G, et al. Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001;161:1429-36
   PubMed Web of Science ®Google Scholar
• Ryan DH, Bray GA, Helmcke F, et al. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999;7:313-22
   PubMedGoogle Scholar